Market leadership Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan with products reaching patients in over 60 countries, presenting cross-border sales opportunities and potential for expansion partnerships in ophthalmology.

Strategic partnerships Recent alliances with KYORIN and AbbVie for distribution and co-promotion indicate a receptiveness to joint marketing and cross-brand collaborations that can be leveraged to introduce new therapies and expand geographic reach, including China and Korea.

Diversified portfolio Santen’s involvement across pharmaceuticals, OTC products, and medical devices for ophthalmology creates multiple upsell avenues with clinics, hospitals, and retailers, as well as potential for device-drug combination strategies.

Growth signals FY2025 revenue and operating profit improvements versus FY2024 suggest financial momentum and a favorable financial health stance for pursuing larger regional BD opportunities, channel expansions, and co-development discussions.

Competitive landscape Active competition with Rohto and other ophthalmology players signals a strong need for differentiated value propositions, including expanded access programs, faster time-to-market collaborations, and targeted ophthalmic product launches.